hotspot -WSS

hotspot

author：explore 2025-09-07 14:00:52 - browse：69641

SAN DIEGO — After starting off the year with lower revenue projections than market analysts had hoped for, San Diego-based genomics giant Illumina lowered expectations again on Wednesday, forecasting annual growth of 1% compared to the previous year.

The market’s response was swift. Minutes after the company issued its press release, shares in Illumina dipped from $184.49 to below $172 during after-hours trading.

In its release, Illumina noted that it expects revenue from the company’s core business to be essentially the same this year compared to last, and that it expects revenue from Grail, the cancer diagnostics company that Illumina acquired for $8 billion in the fall of 2021, to remain in the range of $90 and $100 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Why a market frenzy over new weight loss drugs defies logic

knowledge

WSS

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

STAT Summit: Ending the crisis of Black deaths in the U.S.

Snackable artificial intelligence, expert AI, and the pharma industry

Stem cell treatment guidelines are released by FDA

How to fix cancer clinical trials' diversity problem

Study on Amgen’s bispecific immunotherapy produces positive data

entertainment

hotspot

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Peter Hotez and the public health issue of online harassment

Results on Novartis prostate cancer therapy could expand its use

Malaria cases in Florida and Texas: Here’s what you need to know

AstraZeneca chief proposes a novel edit to the drug pricing bill

Medicare details structure of new drug price negotiation program

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Results on Novartis prostate cancer therapy could expand its use

leisure time

STAT Summit: Ending the crisis of Black deaths in the U.S.

Weighted lottery helped low

CZI to create biohub to build anti

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Health tech investors get more selective as pandemic boom fades

CZI to create biohub to build anti

hotspot

knowledge

focus

focus